- Investing Ideas
- Swiss Pharmaceuticals & Biotech Healthy potentially undervalued
Swiss Pharmaceuticals & Biotech Healthy potentially undervalued
Results
4
Companies which are potentially undervalued and in an acceptable financial position.
4 companies
Tecan Group
Market Cap: CHF 1.9b
Provides laboratory instruments and solutions in biopharmaceuticals, forensics, and clinical diagnostics in Europe, North America, Asia, and internationally.
TECN
CHF 153.60
7D
-2.1%
1Y
-11.2%
Roche Holding
Market Cap: CHF 258.4b
Engages in the pharmaceuticals and diagnostics businesses in Europe, North America, Latin America, Asia, Africa, Australia, and New Zealand.
ROP
CHF 323.90
7D
3.9%
1Y
20.0%
Basilea Pharmaceutica
Market Cap: CHF 602.4m
A Swiss commercial-stage biotech company focused on developing and commercializing treatments for severe bacterial and fungal infections.
BSLN
CHF 48.60
7D
-2.5%
1Y
-6.4%
Bachem Holding
Market Cap: CHF 5.0b
Provides products for research, clinical development, and commercial application to pharmaceutical and biotechnology companies worldwide.
BANB
CHF 67.00
7D
-1.3%
1Y
21.2%